Syndax Pharmaceutical’s Positive Phase 2 Data Supports Potential for Entinostat in Advanced Breast Cancer
– Entinostat in combination with exemestane prolongedprogression-free survival —- Randomized, placebo-controlled data to be in an oralpresentation at ASCO Breast Cancer Symposium 2011 – WALTHAM, Mass., Sept. 6, 2011 /PRNewswire/ –…
September 7th, 2011
Posted in
Drug